When clinicians have to make hard decisions, IQ2™ and ZOE™ trade; provide hard data.

The ability to monitor, evaluate and optimize cardiac performance, pulmonary status and tissue perfusion early in a patient’s treatment, creates the opportunity to optimize therapeutic decision making.

IQ2™ noninvasive hemodynamic monitoring:

• Delivers objective assessment of the heart’s mechanical performance.
• Provides continuous data to optimize fluid management.
  
• Enables precise and rapid titration of diuretics and inotropes.
  Identifies impending onset of shock.
• Optimizes confident goal-directed therapeutic decision making.